This trial is comparing two types of chemotherapy drugs to see which is more effective in treating patients with residual triple negative basal-like breast cancer.
2 Primary · 10 Secondary · Reporting Duration: Assessed at 6 months after randomization
Active Control
Experimental Treatment
415 Total Participants · 3 Treatment Groups
Primary Treatment: Capecitabine · No Placebo Group · Phase 3
Age 18+ · All Participants · 10 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you: